Table 3.
Association Between Immune-Related Adverse Events and the Objective Response Rate and Between Immune-Related Adverse Events and the Increased Post-Treatment Relative Eosinophil Count
| ORR, % | No. of Patients (Responders/Total) | p value | |
|---|---|---|---|
| All patients | 36.2 | 38/105 | |
| Any-grade irAEs | 0.001 | ||
| Yes | 58.8 | 20/34 | |
| No | 25.4 | 18/71 | |
| Grade ≥3 irAEs | 1.000 | ||
| Yes | 36.4 | 4/11 | |
| No | 36.2 | 34/94 | |
| Increased posttreatment REC (3 weeks later) | 0.024 | ||
| Yes | 44.6 | 29/65 | |
| No | 22.5 | 9/40 |
Abbreviations: ORR, objective response rate; irAEs, immune-related adverse events.